Sugi Predict

Sugi Predict / Compounds / SCHEMBL4770967

SCHEMBL4770967

SCHEMBL4770967

CC1CCN(C(=O)N2CCC[C@H](NC(=O)C34CC5CC(C3)C(O)C(C5)C4)C2)CC1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ HSD11B1 P28845 5/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ KMT2A Q03164 2/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ GAA P10253 2/20 0.35
▸ CNR2 P34972 1/20 0.35
▸ CA1 P00915 2/20 0.34
▸ CA2 P00918 2/20 0.34
▸ CA12 O43570 1/20 0.34
▸ CA9 Q16790 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14540867 0.92 EPHX1 (0.46) EPHX1SMN1; SMN2LMNANPSR1HSD11B1
SCHEMBL4794135 0.92 EPHX1 (0.46) EPHX1SMN1; SMN2LMNANPSR1HSD11B1
SCHEMBL4793633 0.91 EPHX1 (0.45) EPHX1SMN1; SMN2LMNANPSR1HSD11B1
SCHEMBL5437855 0.90 EPHX1 (0.52) EPHX1SMN1; SMN2LMNANPSR1HSD11B1
SCHEMBL4767944 0.89 EPHX1 (0.56) EPHX1SMN1; SMN2LMNANPSR1HSD11B1
SCHEMBL5441881 0.89 EPHX1 (0.56) EPHX1SMN1; SMN2LMNANPSR1HSD11B1
SCHEMBL4791230 0.89 EPHX1 (0.45) EPHX1SMN1; SMN2LMNANPSR1HSD11B1
SCHEMBL4767897 0.88 EPHX1 (0.49) EPHX1SMN1; SMN2LMNANPSR1HSD11B1
SCHEMBL4767981 0.88 EPHX1 (0.43) EPHX1SMN1; SMN2LMNANPSR1HSD11B1
SCHEMBL14540688 0.88 EPHX1 (0.49) EPHX1SMN1; SMN2LMNANPSR1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931652-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2008-06-18 — — EP claimed
WO-2007038138-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2007-04-05 — — WO claimed
US-20070066584-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-03-22 — — US claimed
EP-1931652-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2008-06-18 — — EP disclosed
WO-2007038138-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2007-04-05 — — WO disclosed
US-20070066584-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-03-22 — — US disclosed
US-20070066584-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-03-22 — — US disclosed
US-20070066584-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066584-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 EPHX1 378/4885SMN1; SMN2 3627/4885LMNA 2149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.